Fahn, Stanley, 1933-....
Stanley Fahn
Fahn, S.
Fahn, Stanley
VIAF ID: 108744229 (Personal)
Permalink: http://viaf.org/viaf/108744229
Preferred Forms
- 200 _ | ‡a Fahn ‡b Stanley
- 100 1 _ ‡a Fahn, S.
- 100 1 _ ‡a Fahn, Stanley
-
-
-
- 100 1 _ ‡a Fahn, Stanley ‡d 1933-
-
-
-
- 100 1 0 ‡a Fahn, Stanley, ‡d 1933-
-
-
-
- 100 1 _ ‡a Fahn, Stanley, ‡d 1933-....
- 100 0 _ ‡a Stanley Fahn
4xx's: Alternate Name Forms (7)
Works
Title | Sources |
---|---|
Advances in neurology | |
The Assessment and therapy of parkinsonism, c1990: | |
Cerebral hypoxia and its consequences, c1979 (a.e.) | |
Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. 1994. | |
Dystonia 4 | |
Experimental therapeutics of movement disorders | |
Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population | |
Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations | |
Glycine involvement in DDT-induced myoclonus. | |
Hemiparkinsonism-hemiatrophy syndrome may mimic early-stage cortical-basal ganglionic degeneration. | |
High-dosage vitamin E supplementation and all-cause mortality | |
How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both? | |
Huntington's Disease-like 2 (HDL2) in North America and Japan | |
Idiopathic cervical dystonia: clinical characteristics | |
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial | |
Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease | |
Introducing a new journal on Parkinson's disease | |
Lack of Familial Aggregation of Parkinson Disease and Alzheimer Disease | |
Levodopa-induced dyskinesias in autopsy-proven cortical-basal ganglionic degeneration | |
Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind corssover analyses | |
Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents. | |
Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia | |
Manganic encephalopathy due to "ephedrone" abuse | |
The medical treatment of Parkinson disease from James Parkinson to George Cotzias | |
Meige syndrome: primary and secondary forms. | |
Mendelian randomization of serum urate and parkinson disease progression | |
The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies | |
The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography | |
The metabolic topography of idiopathic torsion dystonia | |
More on myoclonus in Alzheimer disease. | |
Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease | |
Movement disorder emergencies diagnosis and treatment | |
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results | |
Movement disorders fellowship training program at Columbia University Medical Center in 2001-2002 | |
Multiple system atrophy in a patient with the spinocerebellar ataxia 3 gene mutation. | |
Multiple System Atrophy With Predominant Striatonigral Degeneration and TAR DNA-Binding Protein of 43 kDa Pathology: An Unusual Variant of Multiple System Atrophy | |
Myoclonus and paroxysmal dyskinesias | |
Myoclonus in complex regional pain syndrome | |
Natural history and treatment of tardive dystonia. | |
Negative motor phenomena | |
Network correlates of disease severity in multiple system atrophy | |
Neurochemical findings in neuroacanthocytosis. | |
Neuroleptic Malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease | |
Neuromelanin detection by magnetic resonance imaging (MRI) and its promise as a biomarker for Parkinson's disease. | |
Neuropathology of lubag (x-linked dystonia parkinsonism). | |
Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study | |
Neurotoxicity of levodopa on catecholamine-rich neurons | |
A new look at levodopa based on the ELLDOPA study | |
Normal erythrocyte uptake of L-DOPA in Parkinson's, Huntington's, and related diseases | |
Normal pressure hydrocephalus and hypertensive cerebrovascular disease. | |
Normalization of brain serotonin by L-tryptophan in levodopa-treated rats | |
The nosology of tardive syndromes. | |
A novel exaggerated "spino-bulbo-spinal like" reflex of lower brainstem origin | |
Oliver Sacks, MD, 1933-2015. | |
Opioid responsiveness in patients with neuroleptic-induced akathisia | |
A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus | |
Principles and practice of movement disorders | |
Psychogenic movement disorders and other conversion disorders | |
Recent developments in Parkinson's disease | |
Stimulus Sensitive Foot Myoclonus: A Clue to Coeliac Disease | |
Striatal 18F-dopa uptake: absence of an aging effect | |
Striatal dopamine in early-onset primary torsion dystonia with the DYT1 mutation. | |
A study of chorea after tetrabenazine withdrawal in patients with Huntington disease | |
Tetrabenazine induces acute dystonic reactions | |
Therapy of Parkinson's disease : four critical issues | |
Tolcapone : COMT Inhibition for the Treatment of Parkinson's disease |